COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors
Alejandro Morales-Ortega 1 , Jaime García de Tena 2 , Begoña Frutos-Pérez 1 , Beatriz Jaenes-Barrios 3 , Ana Isabel Farfán-Sedano 1 , Miguel Ángel Canales-Albendea 4 , David Bernal-Bello 1
In an article previously published in Cancer, Cattaneo et al1 analyzed a cohort of patients with coronavirus disease 2019 (COVID-19) and hematological malignancies in March 2020, and they highlighted that subjects with chronic myeloid leukemia (CML) had a lower than expected frequency of COVID-19. The authors linked this observation to the lower level of immunodeficiency seen in CML and to a potential protective role of tyrosine kinase inhibitors (TKIs) based on the possible antiviral activity of these drugs. However, they reported a mortality rate 30 days after the documentation of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of 50% in the group of patients with chronic myeloproliferative malignancies, which included patients with CML (78% of these patients were treated with TKIs).